Johnson & Johnson said Tuesday it agreed to acquire Guidant Corp. for $21.5 billion in cash and stock under revised terms that value the troubled maker of implantable heart care devices at about $4 billion less than last year’s original offer.
Under the revised agreement, the health care products maker Johnson & Johnson will buy Guidant for about $63.08 per share, down from the original offer of $25.4 billion, or about $76 a share, in December.
